Contrasting Traws Pharma (TRAW) and Its Competitors

Traws Pharma (NASDAQ:TRAW – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Traws Pharma to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, institutional ownership, dividends and earnings.

Risk and Volatility

Traws Pharma has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Traws Pharma’s competitors have a beta of -0.04, meaning that their average stock price is 104% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Traws Pharma and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma 1 4 0 0 1.80
Traws Pharma Competitors 7845 13797 25812 1039 2.41

Traws Pharma presently has a consensus target price of $1.00, suggesting a potential upside of 278.79%. As a group, “Pharmaceuticals” companies have a potential upside of 23.56%. Given Traws Pharma’s higher probable upside, equities analysts plainly believe Traws Pharma is more favorable than its competitors.

Profitability

This table compares Traws Pharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Traws Pharma N/A -23,868.92% -165.52%
Traws Pharma Competitors -2,398.26% -203.62% -15.08%

Valuation and Earnings

This table compares Traws Pharma and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Traws Pharma $2.79 million $9.17 million -0.15
Traws Pharma Competitors $18.55 billion $3.23 billion 562.96

Traws Pharma’s competitors have higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 8.7% of Traws Pharma shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Traws Pharma competitors beat Traws Pharma on 10 of the 13 factors compared.

Traws Pharma Company Profile

(Get Free Report)

Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.

Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.